← Back to Search

Other

Cryoablation Therapy for Breast Cancer

Phase 2
Waitlist Available
Research Sponsored by Alliance for Clinical Trials in Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate breast size for safe cryoablation. Male breast cancer patients and female breast cancer patients with breasts too small to allow safe cryoablation are not eligible
Unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy
Must not have
Patients with lobular carcinoma, multifocal and/or multicentric ipsilateral breast cancer, multifocal calcifications, or DCIS with microinvasion
Prior or planned neoadjuvant chemotherapy for breast cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 14 days post surgery
Awards & highlights

Summary

This study is evaluating whether cryoablation therapy is effective in treating patients with invasive ductal breast cancer.

Who is the study for?
This trial is for individuals with invasive ductal breast cancer confirmed by biopsy, where the tumor is primarily one type of tissue and not larger than 2.0 cm. Participants must not be pregnant or breastfeeding, have no history of similar cancer in the same breast, and should not have received or plan to receive chemotherapy before surgery.
What is being tested?
The study is examining cryoablation therapy—a technique that freezes and destroys tumor cells—as a potential treatment for patients with invasive ductal breast cancer. It's being compared to conventional surgical methods in this phase II trial.
What are the potential side effects?
Cryoablation may cause local pain, redness, bruising at the treatment site, risk of infection, skin numbness or scarring. Conventional surgery could lead to typical surgical risks like bleeding, infection, anesthesia complications and longer recovery time.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast size is suitable for safe cryoablation treatment.
Select...
I have been diagnosed with a single invasive breast cancer through a biopsy.
Select...
I have not had, nor am I planning to have, initial chemotherapy for breast cancer.
Select...
My tumor is mostly not made up of duct-like structures.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My breast cancer is lobular, multifocal, or has spread within the same breast.
Select...
I have had or will have chemotherapy before surgery for breast cancer.
Select...
My tumor is larger than 2.0 cm.
Select...
I have a tumor in the same breast as before.
Select...
I had surgery to remove or examine a lump in my breast for cancer.
Select...
My tumor is more than 25% made up of ductal cells.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 days post surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 days post surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of Complete Tumor Ablation
Secondary study objectives
Negative Predictive Value of MRI

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (cryoablation)Experimental Treatment2 Interventions
A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
therapeutic conventional surgery
2003
Completed Phase 3
~12900
cryosurgery
2007
Completed Phase 3
~110

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Cryoablation therapy treats breast cancer by freezing and destroying tumor cells, which can be particularly useful for patients seeking less invasive options. Other common treatments include surgery, which physically removes the tumor; chemotherapy, which uses drugs to kill rapidly dividing cancer cells; radiation therapy, which uses high-energy rays to target and kill cancer cells; hormone therapy, which blocks hormones that fuel certain cancers; and targeted therapy, which attacks specific molecules involved in cancer growth. Understanding these mechanisms helps patients and doctors choose the most effective treatment plan tailored to the cancer's characteristics and the patient's needs.
Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer.

Find a Location

Who is running the clinical trial?

Alliance for Clinical Trials in OncologyLead Sponsor
512 Previous Clinical Trials
217,373 Total Patients Enrolled
74 Trials studying Breast Cancer
40,044 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,901 Total Patients Enrolled
944 Trials studying Breast Cancer
1,543,865 Patients Enrolled for Breast Cancer
Rache M. Simmons, MDStudy ChairWeill Medical College of Cornell University
1 Previous Clinical Trials
664 Total Patients Enrolled
1 Trials studying Breast Cancer
664 Patients Enrolled for Breast Cancer

Media Library

Cryoablation Therapy (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00723294 — Phase 2
Breast Cancer Research Study Groups: Treatment (cryoablation)
Breast Cancer Clinical Trial 2023: Cryoablation Therapy Highlights & Side Effects. Trial Name: NCT00723294 — Phase 2
Cryoablation Therapy (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00723294 — Phase 2
~6 spots leftby Sep 2025